Search Results
., 2007 ). Researchers once praised MDMA, which increases activity in both systems, as a potential antidepressant ( Riedlinger & Riedlinger, 1994 ). MDMA-assisted treatment for other disorders appear to help depressive symptoms , though those in the
, Wiegand, Taitano, & Delgado, 2006 ), end-of-life anxiety ( Griffiths et al., 2016 ), and substance use disorders ( Johnson, Garcia-Romeu, Cosimano, & Griffiths, 2014 ; Sessa et al., 2021 ). Most notably, the FDA designated MDMA-assisted psychotherapy a
classes: classical psychedelics (e.g. Psilocybin, LSD, DMT), entactogens (e.g. MDMA), dissociative anaesthetics (e.g. Ketamine), and atypical hallucinogens (e.g. Ibogaine). Each of these different classes are characterised by unique pharmacological
subscales. The MEQ-30 has demonstrated sensitivity in assessing the effects of a range of psychedelic compounds, including LSD ( Schmid & Liechti, 2018 ), MDMA ( Lyvers & Meester, 2012 ), psilocybin ( Barrett et al., 2015 ), ayahuasca ( Schenberg, Tofoli
, DMT, and other substances, as seen in Table 1 . Table 1. Lifetime use of hallucinogens Hallucinogen Mean (SD) Median Range LSD 27.51 (104.99) 1.00 0–1,000 Mushrooms 25.64 (94.08) 5.00 0–1,000 MDMA 19.55 (82.7) 0.00 0–5 DMT 3.66 (11.21) 0.00 0
( Depoortere, 1987 ; Marrosu et al., 1995 ; Schneider & Sigg, 1957 ). If an ibogaine protocol is developed and psychotherapy is a part of it, as it is in the MDMA research protocol ( Mithoefer, 2017 ), then it may be worth considering the inclusion of
, M. T. , Reed , S. , & Aggarwal , R. ( 2020 ). Culturally-informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder . Journal of Psychedelic Studies , 4 ( 1 ), 40 – 50 . https://doi.org/10
general public [Bachelor's thesis, University of Twente] . http://purl.utwente.nl/essays/82465 . Therapeutic Goods Administration ( 2023 , Feb 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists
, K. H. , Heifets , B. D. , Hibicke , M. , Mitchell , J. , et al. ( 2021 ). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine . The Journal of Neuroscience: The Official Journal of the
Psychedemia: Charting the future of interdisciplinary Psychedelic Studies
Introduction to the Special Issue
of harm in clinical trials of MDMA. The stakes of adequately communicating these risks to patients is high, especially since P-AT is anticipated as a treatment option for PTSD, which disproportionately impacts historically marginalized groups with
